Kinepict

Make X-ray angiography
safer and more powerful!

About Us

VISION: MAKE X-RAY ANGIOGRAPHY SAFER AND MORE POWERFUL!

MISSION: 10-FOLD REDUCTION IN X-RAY AND

5-FOLD REDUCTION OR ELIMINATION OF IODINATED CONTRAST MEDIA

Using patented kinetic imaging technology one can see the movement of the contrast media based on X-ray image series. This technology presents the bolus movement as a new digital variance angiography (DVA) image. For the latest approach CO2 as contrast media is also applicable.

Technology

REVOLUTIONIZE X-RAY IMAGING BY ADVANCED DATA ANALYSIS!

Kinetic imaging consists of data acquisition and analysis obtained from X-ray image series. The new digital variance angiography (DVA) represents contrast medium motion inside the patient.

The SUI and the DVA are calculated from multiple underexposed images

OUR PRODUCT DEVELOPMENT PROCESSES


Kinetic imaging can visualize blood vessel structures by detecting the movement of the iodinated or CO2 contrast medium bolus. The advanced statistical data analysis yields better image quality than DSA. Replacing DSA with kinetic imaging obtains better image quality, reduced contrast agent amount or X-ray dose.

The SUI and the DVA are calculated from multiple underexposed images

INCREASED DIAGNOSTIC INSIGHT AND CO2 ANGIOGRAPHY


First clinical study, which was published in Radiology (Gyano et al, 2019) proved the DVA visualizes the same structures as DSA but offers dramatically better image quality.

CO2 gas was introduced as a non-toxic contrast agent decades ago. In spite of advantages, a major problem is that CO2 produces lower image quality. Our recent clinical study (Orias et al, 2019) indicated that DVA may bring a paradigm shift in CO2 angiography, because it significantly improves the image quality of angiograms.

The technology is available for clinicians to build an exceptionally powerful angiography suite.

The SUI and the DVA are calculated from multiple underexposed images

CONTRAST MEDIA AND X-RAY DOSE REDUCTION


Our ongoing clinical neuroangiology and lower limb studies indicate that the quality reserve provided by our technology can be effectively converted to significant contrast media (50%) and X-ray dose reduction. This brings significant economical and health benefits - less adverse events, reduced radiation risk - to the medical staff and patients. These clinical results will be published early 2019.

The SUI and the DVA are calculated from multiple underexposed images

Contact Us

Diána Nagy - Sales

+36-31-786-4723

diana.nagy@kinepict.com

Support

+36-31-783-0204

support@kinepict.com

János P. Kiss, MD - Science

+36-31-786-1496

janos.kiss@kinepict.com

Szabolcs Osváth, PhD - CEO

+36-31-782-3748

szabolcs.osvath@kinepict.com

Office

1026, Budapest, Júlia u. 11

kinepict@kinepict.com

Krisztián Szigeti, PhD - CEO

+36-31-782-4019

krisztian.szigeti@kinepict.com

Funding